Last10K.com

Pear Therapeutics, Inc. (PEAR) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

PEAR Annual Reports

  • 10-K Annual Report March 2022

PEAR Registration of Securities

Pear Therapeutics, Inc.

CIK: 1835567 Ticker: PEAR
image_0a.jpg


Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and
Reaffirms Financial and Operational Performance Metrics for Full Year 2022

2021 commercial operational performance metrics, including number of prescriptions, prescription fulfillment rate, and number of covered lives met public guidance
2021 financial results to be announced in March
2022 operational and financial metrics remain unchanged

BOSTON, January 18, 2022 –
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced certain commercial operating performance metrics for full year 2021, all of which met previously provided public guidance. Pear also reaffirms previous public guidance for full year 2022 operational and financial performance metrics.

Full Year 2021

In 2021, Pear delivered strong commercial progress from its portfolio of marketed products across three key performance metrics of prescriptions, fulfillment, and covered lives for which Pear had previously provided public guidance:
More than 550 providers wrote more than 14,000 prescriptions for Pear’s three commercial products, reSET®, reSET-O®, and Somryst®.
Approximately 51% of prescriptions written for Pear’s three commercial products resulted in patients downloading and accessing therapeutic software content. Pear refers to this as fulfillment rate.
More than 30 organizations expanded market access for Pear’s three commercial products to more than 31.7M covered lives.

In each case below, Pear’s commercial operating performance metrics met its previously issued public guidance:
Full Year 2021
Key Operating Performance Metrics(Guidance)(Actual)
Prescriptions12,500
 14,000+
Fulfillment Rate50%
~51%
Covered Lives30M-40M
 31.7M+
“2021 was a transformational year for Pear and for the entire PDT space,” said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. “Pear set out to prove that providers would write prescriptions for PDTs, patients would use them, and payers would pay for them. We succeeded on all three fronts. We are proud of our operational performance metrics in 2021, and we look forward to disclosing our financial results in March.”

Pear began trading on Nasdaq on December 6, 2021. The Company expects to file its Annual Report on Form 10-K, issue its first earnings release, and hold its first earnings call in March 2022.

Pear’s operational performance metrics were facilitated by the achievement of major value-creating milestones, including:

Coverage
More than 30 organizations now provide access to Pear’s PDTs by either listing on a formulary as a covered benefit or purchasing products in bulk. Pear’s PDTs were made available on major national product formularies, including two of the top five pharmacy benefit managers (PBMs).


The following information was filed by Pear Therapeutics, Inc. (PEAR) on Tuesday, January 18, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Pear Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pear Therapeutics, Inc..

Continue

Assess how Pear Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pear Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders??? Deficit
Consolidated Statements Of Financial Condition
Consolidated Statements Of Financial Condition (Parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Details)
Accrued Expenses And Other Current Liabilities (Tables)
Business Combination
Business Combination (Details)
Business Combination (Tables)
Business Combination - Schedule Of Reverse Capitalization (Details)
Business Combination - Warrants (Details)
Capital Stock
Capital Stock (Details)
Capital Stock (Tables)
Capital Stock - Additional Information (Details)
Capital Stock - Convertible Preferred Stock Issuance (Details)
Capital Stock - Schedule Of Convertible Stock (Details)
Capital Stock - Warrants (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Narrative (Details)
Commitments And Contingencies - Operating Leases (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Assets And Fair Value (Details)
Fair Value Measurements - Level 3 Roll Forward (Details)
Fair Value Measurements - Narrative (Details)
Fair Value Measurements - Valuation Assumptions (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Deferred Tax Assets (Details)
Income Taxes - Reconciliation Of Tax Rate (Details)
Indebtedness
Indebtedness (Tables)
Indebtedness - Future Minimum Payments Due (Details)
Indebtedness - Perceptive Credit Facility (Details)
Indebtedness - Schedule Of Debt (Details)
Indebtedness - Svb Term Loan (Details)
Nature Of Business
Nature Of Business - Narrative (Details)
Nature Of Business - Organization (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Antidilituve Securities (Details)
Net Loss Per Share - Basic And Diluted Per Share (Details)
Past Collaboration And License Agreement
Past Collaboration And License Agreement - Novartis (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Common Stock Options (Details)
Stock-Based Compensation - Espp (Details)
Stock-Based Compensation - Narrative (Details)
Stock-Based Compensation - Stock Based Compensation Expense (Details)
Stock-Based Compensation - Valuation Assumptions (Details)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Cash, Cash Equivalents And Restricted Cash (Details)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - New Accounting Pronouncements (Details)
Summary Of Significant Accounting Policies - Property And Equipment (Details)
Summary Of Significant Accounting Policies - Warrants And Revenue (Details)
Ticker: PEAR
CIK: 1835567
Form Type: 10-K Annual Report
Accession Number: 0001835567-22-000010
Submitted to the SEC: Mon Mar 28 2022 6:22:11 PM EST
Accepted by the SEC: Tue Mar 29 2022
Period: Friday, December 31, 2021
Industry: Health Services

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/pear/0001835567-22-000010.htm